PathToScale: An Implementation Evaluation

This study evaluates the rollout of a long-acting injectable HIV prevention medication called cabotegravir (CAB-LA) — given every 2 months by injection — as an alternative to daily oral PrEP pills for people at high risk of HIV infection. **You may be eligible if...** - You are 15 years of age or older - You belong to one of the following groups at high risk for HIV: female sex workers, men who have sex with men, transgender individuals, women and young women seeking STI or family planning services, breastfeeding women, or male partners of sex workers - You are HIV-negative **You may NOT be eligible if...** - You are already HIV-positive - You have health conditions or circumstances that make injectable PrEP unsafe for you according to your healthcare provider Talk to your doctor to see if this trial is right for you.